A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia

Fanconi Anemia Clinical Trial

Official title:

A Multinational, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of FP 045 in Patients With Fanconi Anemia (FusuciA Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04522375
• Other study ID #: FP045C-19-001
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: June 30, 2023
• Est. completion date: December 2025

Study information

• Verified date: May 2023
• Source: Foresee Pharmaceuticals Co., Ltd.
• Contact: Bassem Elmankabadi, MD
• Phone: 562 310-8718
• Email: Bassem.elmankabadi[@]foreseepharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, Phase 1/2 study to determine the Optimal Biologic Dose (OBD) and to evaluate the safety, tolerability, PK, and preliminary activity of FP 045 when administered orally in young adult/adolescent and pediatric patients with Fanconi anemia. The study will enroll a total of 6 young adult/adolescent patients and a minimum of 8 and up to 12 pediatric patients with mild-moderate bone marrow failure who have not undergone hematopoietic cell transplant. This makes the total patient number between 14-18 total. Dose escalation will occur individually for each patient, within each age group. Each patient will receive each of 3 dose levels of FP 045 (intra-patient dose escalation), beginning with Dose Level 1, followed by Dose Levels 2 and 3. Each dose level will be administered for 28 days prior to escalation to the next higher dose level for that patient.

Description:

Dose escalation will begin with young adult/adolescent patients. The initial two patients enrolled in the study will be > 15 years of age. These patients must complete the entire 28-day period of treatment at Dose Level 1 prior to additional young adult/adolescent patients being enrolled. All 6 young adult/adolescent patients must complete 28 days of treatment at Dose Level 1, and cumulative safety must be reviewed by the Safety Review Committee (SRC), prior to the enrollment of pediatric patients. The initial two pediatric patients enrolled will be > 6 years of age. These patients must complete the entire 28-day period of treatment at Dose Level 1 prior to additional pediatric patients being enrolled. A minimum of 8 and maximum of 12 pediatric patients will be enrolled to allow for at least 4 patients between the ages of 3-6. Study assessments will be conducted at each visit. Patients will be observed closely for Dose Limiting Toxicity (DLT) during each dosing period. Any patient experiencing a DLT will have study drug interrupted and will not be allowed to escalate to the next higher dose level. The patient may resume treatment at one dose level lower once the DLT has resolved to baseline or to ≤ Grade 1 in severity. The MTD will be defined as the dose level immediately below the dose level at which DLT occurred. Patients requiring an interruption in treatment of > 3 weeks following a DLT will be withdrawn from the study. The MTD will be assessed separately for each individual patient. Following the completion of dose escalation, each patient will continue treatment at either the highest dose or their individual MTD, and then transition to the OBD for their age group (once defined), for a total of 3 months. Patients failing to receive 75% of planned doses for reasons other than adverse effects may be replaced.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 18
• Est. completion date: December 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 25 Years

Eligibility

Inclusion Criteria:

• male or female aged 3-25
• documented Fanconi anemia by chromosome breakage analysis
• females of child-bearing potential and males required to use highly effective birth control
• mild to moderate bone marrow failure with at least one cytopenia of > grade 1 severity

Exclusion Criteria:

• history of any malignancy except focal squamous cell or basal cell carcinoma of the skin or carcinoma in situ of cervix
• has myelodysplastic syndrome or acute leukemia per world health organization (WHO) criteria
• has history of any significant medical conditions
• has aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 5x upper limit of normal (ULN) or calculated creatinine clearance (Clcr) of < 50 mL/min
• has active Hepatitis B or C
• has an ongoing systemic infection
• requires a strong CYP3A4 inhibitor
• has had major surgery within 30 days
• Active graft versus host disease requiring systemic treatment
• Has a history of bone marrow or stem cell transplant

Related Conditions & MeSH terms

• Anemia
• Fanconi Anemia
• Fanconi Syndrome

Intervention

Drug:
• FP-045
activator of aldehyde dehydrogenase

Locations

Country	Name	City	State
United States	St. Jude Childrens Research Hospital	Memphis	Tennessee
United States	Masonic Cancer Center, University of Minnesota	Minneapolis	Minnesota
United States	David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center	New York	New York
United States	Lucille Packard Children's Hospital, Stanford University	Palo Alto	California

Sponsors (1)

Lead Sponsor	Collaborator
Foresee Pharmaceuticals Co., Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Optimal Biologic Dose (OBP) of FP-045	The OBP of FP-045 in adolescent and pediatric subjects	28 days x up to 3 doses
Primary	stabilizing or improving cytopenia in FA	Change from baseline in hemoglobin	3 months
Secondary	Safety and tolerability	Frequency of adverse events and serious adverse events	3-6 months
Secondary	pharmacokinetic profile	Mean AUC of FP-045 by dose level	3- 6 months